The drug helping premature babies breathe is pulmonary surfactant, a lipoprotein complex that is administered directly into the lungs to prevent the tiny air sacs from collapsing. Before surfactant therapy became available, extremely premature infants weighing under 1,500 grams had a survival rate of roughly 5 percent. Today, thanks to this treatment, that figure has climbed to upwards of 90 percent — one of the most dramatic improvements in the history of neonatal medicine. Surfactant is a substance the body produces naturally, but premature babies often arrive before their lungs have had a chance to make enough of it.
The lung surfactant system does not begin developing until around 24 weeks of gestation, and adequate production does not kick in until approximately 32 weeks. When a baby is born before that window closes, the result is Respiratory Distress Syndrome, a condition where fluid fills the lungs and the alveoli collapse with each breath. Administering synthetic or animal-derived surfactant through a tube placed into the windpipe can stabilize those fragile air sacs within minutes. This article covers how surfactant works at the cellular level, the FDA-approved drugs currently in use, emerging synthetic alternatives, less-invasive delivery methods, and what families and clinicians should know about the latest research heading into 2026.
Table of Contents
- How Does Pulmonary Surfactant Help Premature Babies Breathe?
- FDA-Approved Surfactant Drugs and How They Compare
- The Connection Between Premature Birth, Brain Health, and Long-Term Development
- Less-Invasive Surfactant Delivery — A Gentler Approach
- When CPAP Fails and Timing Becomes Critical
- The Promise of Fully Synthetic Surfactant
- What the Future Holds for Surfactant Therapy
- Conclusion
- Frequently Asked Questions
How Does Pulmonary Surfactant Help Premature Babies Breathe?
To understand what surfactant does, picture a cluster of tiny wet balloons — the alveoli — that must inflate and deflate thousands of times per hour. Water molecules on the inner surface of each balloon create surface tension, a force that tries to pull the walls inward and collapse the sac. In a full-term infant, surfactant coats that inner lining and dramatically reduces surface tension at the liquid-air interface, making it far easier for the alveoli to stay open during exhalation. Without it, a premature baby must work enormously hard just to keep those air sacs from sticking shut, and many cannot sustain the effort. When surfactant is delivered via intratracheal administration — meaning through a tube threaded into the windpipe and down into the lungs — the effects are rapid. Clinicians typically see improvements in oxygenation and lung compliance within minutes.
The drug stabilizes the alveoli, decreases the mechanical work of breathing, and reduces the risk of pneumothoraces, which are collapsed lungs caused by the rupture of over-stressed tissue. For a baby born at 26 weeks who weighs barely more than a pound, this intervention is often the difference between life and death. It is worth noting that surfactant therapy is not a one-and-done cure. Some infants require multiple doses, and the treatment addresses the immediate crisis rather than the underlying immaturity of the lungs. Babies who receive surfactant still frequently need supplemental oxygen and ventilatory support for days or weeks afterward. The drug buys time — critical, life-saving time — for the lungs to continue developing outside the womb.
FDA-Approved Surfactant Drugs and How They Compare
Several surfactant preparations have received FDA approval over the years, and they fall into two broad categories: animal-derived and synthetic. On the animal-derived side, Curosurf (poractant alfa) is extracted from porcine lung tissue and has a surfactant protein B content of about 30 percent, making it one of the more protein-rich options available. Survanta (beractant) is a modified bovine lung extract that has been a mainstay in neonatal intensive care units for decades. Infasurf (calfactant) comes from calf lung tissue and is another widely used natural preparation. The synthetic category took a significant step forward on March 6, 2012, when the FDA approved Surfaxin (lucinactant), the first synthetic, peptide-containing surfactant for neonatal use. In clinical trials, Surfaxin demonstrated significant improvement in RDS at 24 hours after birth and lower RDS-related mortality through two weeks compared with older synthetic surfactants that lacked peptide components.
The appeal of a synthetic option is clear: it does not depend on animal tissue sourcing, which can introduce variability in composition and raise supply chain concerns. However, the choice of surfactant is not always straightforward. Head-to-head trials have shown differences in dosing volumes, protein content, and speed of response, but no single product has emerged as universally superior across all patient populations. Clinicians often base their selection on institutional experience, availability, and the specific clinical scenario. A baby born at 25 weeks with severe RDS may benefit from a higher-protein preparation like Curosurf, while supply constraints or cost considerations in resource-limited settings may favor whatever product is reliably on hand. The critical point is that any surfactant is vastly better than none.
The Connection Between Premature Birth, Brain Health, and Long-Term Development
For readers of a brain health and dementia care site, the relevance of neonatal surfactant therapy may not be immediately obvious — but the connection is real and deeply studied. Oxygen deprivation in the first hours and days of life can cause lasting neurological damage. When a premature infant’s lungs fail to exchange gases efficiently, the brain is among the first organs to suffer. Periventricular leukomalacia, intraventricular hemorrhage, and diffuse white matter injury are all more common in babies who experience prolonged respiratory failure. By stabilizing the lungs quickly, surfactant therapy reduces the duration and severity of hypoxic episodes.
This does not eliminate the risk of neurodevelopmental problems — prematurity itself carries inherent vulnerabilities — but it meaningfully shifts the odds. Large cohort studies following extremely premature infants into adulthood have found that survivors from the post-surfactant era have better cognitive outcomes on average than those born in the decades before surfactant was available. Some of these individuals are now in their 30s and 40s, and researchers are beginning to ask whether the early lung and brain insults of extreme prematurity influence the trajectory of cognitive aging. This is an area of active investigation. There is not yet enough longitudinal data to say definitively whether adults born extremely premature face elevated dementia risk later in life, but early indicators suggest that some experience accelerated changes in brain structure and function compared with their full-term peers. Surfactant therapy, by limiting early brain injury, may prove to be one of the interventions that shapes cognitive health across the entire lifespan.
Less-Invasive Surfactant Delivery — A Gentler Approach
Traditional surfactant administration requires endotracheal intubation, a procedure in which a tube is passed through the vocal cords and into the trachea. While effective, intubation itself carries risks: airway trauma, hemodynamic instability, and the need for mechanical ventilation, which can injure developing lung tissue and contribute to bronchopulmonary dysplasia. In recent years, a technique known as Less-Invasive Surfactant Administration, or LISA, has gained significant traction as an alternative. With LISA, surfactant is delivered through a thin, flexible catheter threaded into the trachea while the baby continues breathing on continuous positive airway pressure, or CPAP, without full intubation. Multiple randomized clinical trials are currently ongoing to refine the technique and establish clearer guidelines for its use.
The theoretical advantage is compelling: the baby receives the surfactant it needs without being subjected to the mechanical ventilation that often follows traditional intubation. Early data suggest that LISA is both safe and effective, though it requires skilled practitioners and is not yet universally adopted. The tradeoff is one of technique versus access. LISA demands a certain level of operator experience and equipment that may not be available in every delivery room, particularly in lower-resource settings. Moreover, not every baby is a candidate — the most critically ill infants who are already in respiratory failure may still require conventional intubation and mechanical ventilation. For the subset of moderately premature babies who are breathing on their own but struggling, LISA represents a meaningful advance in gentler care.
When CPAP Fails and Timing Becomes Critical
Not every premature infant needs surfactant immediately. Many neonatal units now start with CPAP as a first-line intervention, reserving surfactant for babies who do not respond adequately. But studies have shown that this watch-and-wait approach has limits. Research reports that 43 percent of infants born at 25 to 28 weeks experience CPAP failure within 72 hours, ultimately requiring surfactant and mechanical ventilation anyway. The timing of surfactant administration matters enormously. Updated clinical thresholds now recommend that for preterm neonates born at or before 30 weeks of gestation, surfactant should be considered when the fraction of inspired oxygen, or FiO2, reaches 40 percent.
Waiting too long can allow lung injury to accumulate, making the surfactant less effective when it is finally given and increasing the risk of bronchopulmonary dysplasia — a chronic lung condition that can follow premature infants for years. Research is particularly focused on the most immature subgroup, babies born before 28 weeks, where surfactant timing directly impacts rates of BPD. For these infants, the window between “too early” and “too late” is narrow. Giving surfactant prophylactically to every baby in this group exposes some who would have done fine on CPAP alone to an unnecessary invasive procedure. But delaying too long in the name of avoiding intervention can result in worse lung and brain outcomes. Clinicians walk this line daily, and the evidence base is still evolving.
The Promise of Fully Synthetic Surfactant
One of the most exciting developments in surfactant research is the creation of a fully synthetic version designed to mimic the composition and function of natural calf-lung-derived surfactant like Infasurf. Scientists have engineered this new surfactant from synthetic lipids and peptides, eliminating the need for animal tissue entirely.
If it reaches clinical use, it could provide a cheaper, more readily available alternative — particularly important in parts of the world where the cold-chain storage and animal sourcing required for current products pose significant barriers. A fully synthetic surfactant that performs comparably to animal-derived versions would also remove batch-to-batch variability, a known issue with biological products. While this work is still in the development stage and has not yet reached FDA approval, it represents the kind of innovation that could expand access to this life-saving therapy for premature infants in low- and middle-income countries where RDS remains a leading cause of neonatal death.
What the Future Holds for Surfactant Therapy
Looking ahead, the field is converging on several priorities: refining LISA techniques to make them standard of care, establishing more precise clinical thresholds for when to administer surfactant in the CPAP era, and advancing synthetic formulations through clinical trials. The ultimate goal is a surfactant that is affordable, shelf-stable, easy to administer without intubation, and effective across the full spectrum of gestational ages. For those interested in brain health and cognitive aging, the surfactant story is also a reminder that neurological well-being does not begin in middle age.
It begins in the first minutes of life. Every intervention that protects the neonatal brain from oxygen deprivation — surfactant therapy chief among them — is an investment in lifelong cognitive resilience. As the generation of extremely premature survivors grows older, understanding how their early respiratory care shapes their later brain health will become an increasingly important area of research.
Conclusion
Pulmonary surfactant therapy stands as one of modern medicine’s clearest success stories. A treatment that moved survival rates for the smallest premature infants from roughly 5 percent to over 90 percent deserves its place among the most important pharmaceutical advances of the past half century. With FDA-approved options ranging from porcine and bovine preparations like Curosurf, Survanta, and Infasurf to the synthetic Surfaxin, clinicians have real choices — and the development of next-generation fully synthetic surfactants promises to make the therapy even more accessible worldwide.
The work ahead is about refinement: better timing, gentler delivery, broader access, and deeper understanding of how early respiratory care influences long-term neurological outcomes. For families navigating a premature birth, knowing that surfactant therapy exists and works rapidly can provide a measure of reassurance during an extraordinarily stressful time. And for anyone thinking about brain health across the lifespan, the surfactant story is a powerful illustration that protecting the brain starts with the very first breath.
Frequently Asked Questions
What is pulmonary surfactant and why do premature babies need it?
Pulmonary surfactant is a lipoprotein complex made of proteins and phospholipids that coats the alveoli in the lungs and reduces surface tension to keep them from collapsing. Premature babies need exogenous surfactant because their lungs have not yet produced enough of their own — the surfactant system does not begin developing until 24 weeks of gestation, and adequate amounts are not produced until around 32 weeks. Without it, premature infants develop Respiratory Distress Syndrome.
How is surfactant administered to newborns?
Surfactant is traditionally administered via intratracheal delivery, meaning it is instilled directly into the lungs through a tube placed in the windpipe. A newer approach called Less-Invasive Surfactant Administration, or LISA, uses a thin catheter to deliver the drug while the baby continues breathing on CPAP, avoiding full intubation.
How quickly does surfactant therapy work?
The effects of surfactant therapy are seen rapidly after administration. Clinicians typically observe improvements in oxygenation and lung compliance within minutes of delivery, though some infants may require additional doses.
Are there risks or limitations to surfactant therapy?
Surfactant therapy addresses the immediate respiratory crisis but does not cure the underlying lung immaturity. Some babies need multiple doses, and many still require supplemental oxygen or mechanical ventilation afterward. The traditional delivery method requires intubation, which carries its own risks including airway trauma and the potential for ventilator-induced lung injury.
Can surfactant therapy affect long-term brain development?
By stabilizing the lungs and improving oxygen exchange quickly, surfactant therapy reduces the duration of hypoxic episodes that can damage the developing brain. While it does not eliminate the neurological risks associated with prematurity, studies suggest that infants treated in the post-surfactant era have better cognitive outcomes on average than those born before the therapy was available.
What is the newest development in surfactant research?
Scientists have developed a fully synthetic surfactant made from synthetic lipids and peptides designed to mimic natural calf-lung surfactant. This could provide a cheaper, more readily available alternative that does not rely on animal tissue, potentially expanding access in lower-resource settings worldwide.
